BNTC vs. SBTX, NKTX, NBTX, URGN, QTTB, AVIR, VTYX, KMDA, ADCT, and VNDA
Should you be buying Benitec Biopharma stock or one of its competitors? The main competitors of Benitec Biopharma include Silverback Therapeutics (SBTX), Nkarta (NKTX), Nanobiotix (NBTX), UroGen Pharma (URGN), Q32 Bio (QTTB), Atea Pharmaceuticals (AVIR), Ventyx Biosciences (VTYX), Kamada (KMDA), ADC Therapeutics (ADCT), and Vanda Pharmaceuticals (VNDA). These companies are all part of the "pharmaceutical preparations" industry.
Benitec Biopharma (NASDAQ:BNTC) and Silverback Therapeutics (NASDAQ:SBTX) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, profitability, earnings, dividends, media sentiment, valuation, community ranking, risk and analyst recommendations.
Benitec Biopharma has higher revenue and earnings than Silverback Therapeutics.
Benitec Biopharma received 163 more outperform votes than Silverback Therapeutics when rated by MarketBeat users. Likewise, 63.73% of users gave Benitec Biopharma an outperform vote while only 56.25% of users gave Silverback Therapeutics an outperform vote.
In the previous week, Benitec Biopharma had 2 more articles in the media than Silverback Therapeutics. MarketBeat recorded 3 mentions for Benitec Biopharma and 1 mentions for Silverback Therapeutics. Benitec Biopharma's average media sentiment score of 1.58 beat Silverback Therapeutics' score of 0.00 indicating that Benitec Biopharma is being referred to more favorably in the media.
Silverback Therapeutics' return on equity of -29.62% beat Benitec Biopharma's return on equity.
52.2% of Benitec Biopharma shares are held by institutional investors. Comparatively, 74.9% of Silverback Therapeutics shares are held by institutional investors. 4.3% of Benitec Biopharma shares are held by insiders. Comparatively, 34.4% of Silverback Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Benitec Biopharma has a beta of 0.8, meaning that its share price is 20% less volatile than the S&P 500. Comparatively, Silverback Therapeutics has a beta of 0.6, meaning that its share price is 40% less volatile than the S&P 500.
Benitec Biopharma presently has a consensus price target of $16.00, indicating a potential upside of 109.15%. Given Benitec Biopharma's higher probable upside, research analysts clearly believe Benitec Biopharma is more favorable than Silverback Therapeutics.
Summary
Benitec Biopharma beats Silverback Therapeutics on 9 of the 13 factors compared between the two stocks.
Get Benitec Biopharma News Delivered to You Automatically
Sign up to receive the latest news and ratings for BNTC and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding BNTC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Benitec Biopharma Competitors List
Related Companies and Tools
